吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

未开盘 04-29 16:00:00 EDT

65.94

+0.52

+0.79%

盘后66.00

+0.06+0.09%

19:59 EDT

最高66.91	最低65.20	成交量783.85万
今开65.30	昨收65.42	日振幅2.61%
总市值822.25亿	流通市值820.52亿	总股本12.47亿
成交额5.19亿	换手率0.63%	流通股本12.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":65.94,"timestamp":1714420800000,"preClose":65.42,"halted":0,"volume":7838526,"hourTrading":{"tag":"盘后","latestPrice":66,"preClose":65.94,"latestTime":"19:59 EDT","volume":769251,"amount":50724622.378,"timestamp":1714435153114},"delay":0,"floatShares":1244337698,"shares":1246969303,"eps":4.5,"marketStatus":"未开盘","marketStatusCode":0,"change":0.52,"latestTime":"04-29 16:00:00 EDT","open":65.3,"high":66.91,"low":65.2,"amount":518705286.97458,"amplitude":0.026139,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.5,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714464000000},"adr":0,"listingDate":696056400000,"adjPreClose":65.42,"adrRate":0,"dividendRate":0.045799,"preHourTrading":{"tag":"盘前","latestPrice":65.05,"preClose":65.42,"latestTime":"09:28 EDT","volume":22899,"amount":1476599.743446,"timestamp":1714397280049},"postHourTrading":{"tag":"盘后","latestPrice":66,"preClose":65.94,"latestTime":"19:59 EDT","volume":769251,"amount":50724622.378,"timestamp":1714435153114},"volumeRatio":0.835958,"optionData":{"bulkOrders":[{"symbol":"GILD","call":true,"expireDate":1718942400000,"strike":"67.5","timestamp":1714402518895,"price":1.5800000429153442,"volume":14784,"amount":2335872,"type":"-"},{"symbol":"GILD","call":true,"expireDate":1715918400000,"strike":"68.0","timestamp":1714413763847,"price":0.5799999833106995,"volume":2999,"amount":173942,"type":"*"}]}},"requestUrl":"/m/hq/s/GILD/","defaultTab":"news","newsList":[{"id":"2430526990","title":"49亿美金赌注归零，吉利德出局CD47背后","url":"https://stock-news.laohu8.com/highlight/detail?id=2430526990","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2430526990?lang=zh_cn&edition=full","pubTime":"2024-04-28 20:47","pubTimestamp":1714308451,"startTime":"0","endTime":"0","summary":"2020年3月份，吉利德科学掷下重金，以49亿美元的价格，收购了专门研究针对CD47靶点免疫疗法的ForthSeven。日前，在公布一季度财报的同时，吉利德更新了管线进展，其中关于CD47单抗Magrolimab的6项实体瘤临床被全部剔除。这也意味着，吉利德已经彻底“认输”。作为CD47抗体研发最快的选手，Magrolimab出局无疑令人扼腕。只是，目前来看，吉利德的下注并不成功。只是，目前来看，这个改造似乎不足以解决CD47抗体的血液毒性问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404282053018b5ded91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404282053018b5ded91&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430742734","title":"吉利德科学2024财年第一财季实现净利润-41.70亿美元，同比减少512.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430742734","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430742734?lang=zh_cn&edition=full","pubTime":"2024-04-28 00:26","pubTimestamp":1714235168,"startTime":"0","endTime":"0","summary":"3月31日，吉利德科学公布财报，公告显示公司2024财年第一财季净利润为-41.70亿美元，同比减少512.46%；其中营业收入为66.86亿美元，同比增加5.66%，每股基本收益为-3.34美元。从资产负债表来看，吉利德科学总负债388.37亿美元，其中短期债务--，资产负债比为1.45，流动比率为0.98。机构评级：截至2024年3月31日，当前有25家机构对吉利德科学目标价做出预测，其中目标均价为83.95美元，其中最低目标价为69.00美元，最高目标价为120.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042800261087b7d3c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042800261087b7d3c1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430339200","title":"加拿大皇家银行：维持Gilead Sciences(GILD.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由76.00美元调整至74.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2430339200","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430339200?lang=zh_cn&edition=full","pubTime":"2024-04-26 23:55","pubTimestamp":1714146935,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Gilead Sciences(GILD.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由76.00美元调整至74.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042623553887b45445&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042623553887b45445&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430922234","title":"Needham：重申Gilead Sciences(GILD.US)持有评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2430922234","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430922234?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:36","pubTimestamp":1714127761,"startTime":"0","endTime":"0","summary":"Needham：重申Gilead Sciences(GILD.US)持有评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261836048b56d941&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261836048b56d941&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430210781","title":"吉利德科学：一季度产品销售总额66亿美元 同比增长5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430210781","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2430210781?lang=zh_cn&edition=full","pubTime":"2024-04-26 15:01","pubTimestamp":1714114907,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，吉利德科学发布2024年第一季度财务报告，一季度产品销售总额66亿美元，同比增长5%。其中，HIV产品销售额43亿美元，同比增长4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404263061137045.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404263061137045.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430177832","title":"吉利德科学第一季度产品销售总额66亿美元，同比增长5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430177832","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2430177832?lang=zh_cn&edition=full","pubTime":"2024-04-26 14:46","pubTimestamp":1714113978,"startTime":"0","endTime":"0","summary":"吉利德科学当地时间4月25日公布2024年第一季度财报，第一季度产品销售总额同比增长5%，达66亿美元；必妥维销售额同比增长10%，达29亿美元；肿瘤产品销售额同比增长18%，达7.89亿美元；瑞德西韦销售额5.55亿美元，同比下降3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261446197a55ff18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261446197a55ff18&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430826286","title":"吉利德科学一季度营收66.9亿美元，高于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430826286","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430826286?lang=zh_cn&edition=full","pubTime":"2024-04-26 08:23","pubTimestamp":1714090982,"startTime":"0","endTime":"0","summary":"吉利德科学一季度每股亏损1.32美元，分析师预期亏损1.52美元。一季度营收66.9亿美元，分析师预期63.4亿美元。一季度Veklury营收5.55亿美元，分析师预期3.778亿美元。预计全年调整后EPS为3.45-3.85美元，公司之前预计6.85%-7.25美元。维持全年产品(产量)预期不变。公司短期内不会涉足任何重大的并购交易。2月销量暂时性地遭受与调整医保相关的网络袭击的干扰，3月份已经恢复正常。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260835328b54c81a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260835328b54c81a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430261205","title":"吉利德彻底放弃CD47单抗开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2430261205","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2430261205?lang=zh_cn&edition=full","pubTime":"2024-04-26 07:54","pubTimestamp":1714089256,"startTime":"0","endTime":"0","summary":"4月22日，吉利德在公布2024Q1财报的同时，更新了管线进展，其将关于CD47单抗magrolimab的6项试验从管线中剔除。今年2月7日，吉利德宣布，终止magrolimab所有血液瘤项目开发，短短10天后，其又宣布magrolimab实体瘤临床试验遭FDA暂停。而此次6项试验从管线中移除意味着吉利德彻底放弃该款药物的开发。以Magrolimab为代表的CD47靶点曾被认为是下一个重磅炸弹诞生地，然而，该靶点药物开发最终还是以失败告终。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042607571787b0f7e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042607571787b0f7e6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430265090","title":"吉利德科学公司（Gilead Sciences Inc）公布截至三月份的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2430265090","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430265090?lang=zh_cn&edition=full","pubTime":"2024-04-26 07:08","pubTimestamp":1714086524,"startTime":"0","endTime":"0","summary":"   * 吉利德科学公司公布了截至 3 月份的季度调整后每股亏损 1.32 美元，低于去年同期的每股亏损 1.37 美元。23 位分析师对该季度的平均预期是每股亏损 1.49 美元。华尔街预期为每股亏损 1.86 美元至 1.14 美元。* 吉利德科学公司公布的本季度每股收益为亏损 3.34 美元。* 该公司一季度亏损 41.7 亿美元。* 吉利德科学公司本季度股价下跌了 8.4%，今年迄今为止下跌了 17.2%。华尔街对吉利德科学公司 12 个月目标价的中位数为 80.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430562022","title":"吉利德公布季度亏损，收入增长 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2430562022","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430562022?lang=zh_cn&edition=full","pubTime":"2024-04-26 04:02","pubTimestamp":1714075379,"startTime":"0","endTime":"0","summary":" Deena Beasley    路透社4月25日 - 吉利德科学公司  周四公布了第一季度亏损报告，该公司因最近收购肝病药物开发商CymaBay Therapeutics而被计提了39亿美元的费用。吉利德公布的调整后季度每股亏损为 1.32 美元，好于分析师预测的每股亏损 1.48 美元。按净额计算，吉利德公司的季度亏损为每股 3.34 美元。吉利德的肿瘤学销售额增长了 18%，达到 7.89 亿美元。他指出，吉利德预计今年将有几个关键项目的试验结果，包括抗癌药物 Trodelvy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430538712","title":"BUZZ-前瞻：吉利德科学公司下跌超过 2%，将于收盘后发布财报","url":"https://stock-news.laohu8.com/highlight/detail?id=2430538712","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430538712?lang=zh_cn&edition=full","pubTime":"2024-04-26 02:48","pubTimestamp":1714070919,"startTime":"0","endTime":"0","summary":"    4月25日 - ** 吉利德科学公司  的股价在周四下午的交易中下跌了2.6%，该公司将在收盘后公布季度业绩。** 根据伦敦证券交易所集团的数据，吉利德预计其营业收入将从一年前的63.5亿美元降至63.4亿美元，每股亏损1.49美元，而去年同期每股盈利1.37美元。** 根据LSEG的数据，该公司在过去8个报告期中，有6个报告期的盈利超过了分析师的预期。** 包括本交易日的走势在内，吉利德今年迄今下跌了19%，而同期标准普尔500指数  上涨了6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430890082","title":"吉利德科学下跌1.37%，报66.16美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430890082","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430890082?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:01","pubTimestamp":1714053687,"startTime":"0","endTime":"0","summary":"4月25日，吉利德科学(GILD)盘中下跌1.37%，截至22:01，报66.16美元/股，成交6962.42万美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学(美东)盘后披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25220140414670.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430462500","title":"未来一天的看点 - 4月25日星期四","url":"https://stock-news.laohu8.com/highlight/detail?id=2430462500","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430462500?lang=zh_cn&edition=full","pubTime":"2024-04-25 02:30","pubTimestamp":1713983434,"startTime":"0","endTime":"0","summary":"美国劳工部的每周失业救济申请数据可能会显示，在截至4月20日的一周内，各州首次申请失业救济的人数增加了3000人，经季节性因素调整后为215000人。与此同时，首次领取失业救济金的人数可能从截至4月13日当周的181.2万人降至180.5万人。美国航空公司将公布第一季度财报。由于主要市场需求低迷，陶氏预计将公布第一季度收入下降的报告。烟草巨头 Altria 将公布第一季度业绩。受客户转向广告流媒体的帮助，Roku 第一季度收入预计将增长 14.52%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429400841","title":"吉利德科学公司  预计每股亏损1.51美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429400841","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429400841?lang=zh_cn&edition=full","pubTime":"2024-04-24 05:19","pubTimestamp":1713907181,"startTime":"0","endTime":"0","summary":"   * 吉利德科学公司   将于4月25日公布截至2024年3月31日的财报，预计该公司的季度收入将出现下降。   * LSEG 分析师对吉利德科学公司的平均预期是每股亏损 1.51 美元。* 华尔街对吉利德科学公司 12 个月目标价的中位数为 80.00 美元，高于其上次收盘价 66.95 美元。4月23日 - 以前季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428668911","title":"美国研究综述-Blackstone、Ellington Financial、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2428668911","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428668911?lang=zh_cn&edition=full","pubTime":"2024-04-19 15:24","pubTimestamp":1713511479,"startTime":"0","endTime":"0","summary":"    路透社4月19日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括黑石集团、艾灵顿金融公司和 Netflix。要闻              * 黑石集团  ：Piper Sandler 将目标价从 146 美元下调至 143 美元             * Ellington Financial Inc   ：Jonestrading 给予其 \"持有 \"评级             * Netflix Inc   ：Pivotal Research将目标价从765美元上调至800美元 以下是路透社周五报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428567780","title":"瑞银：维持Gilead Sciences(GILD.US)评级，由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428567780","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428567780?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:36","pubTimestamp":1713440183,"startTime":"0","endTime":"0","summary":"瑞银：维持Gilead Sciences(GILD.US)评级，由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181936268b35e18e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181936268b35e18e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426783006","title":"BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2426783006","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426783006?lang=zh_cn&edition=full","pubTime":"2024-04-12 19:37","pubTimestamp":1712921821,"startTime":"0","endTime":"0","summary":"    4月12日 - ** Nurix Therapeutics Inc 的    股价在隔夜后续定价后盘前下跌 5.3%，报 16.30 美元。** 生物制药公司周四晚些时候宣布，  ~1170万股，包括150万份预筹资认股权证，发行价为15美元，筹资总额为1.75亿美元。** Nurix本月早些时候宣布延长与吉利德科学公司  的合作。2023 年第四季度，该公司与辉瑞  达成新的合作。** Nurix 拥有约 4 920 万股已发行股票，市值约 8.46 亿美元** 截至本周四，公司股价已累计上涨 67** 摩根大通、Piper Sandler 和 Stifel 担任股票发行的账簿管理人","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426296458","title":"吉利德科学上涨1.25%，报68.97美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426296458","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426296458?lang=zh_cn&edition=full","pubTime":"2024-04-12 02:08","pubTimestamp":1712858894,"startTime":"0","endTime":"0","summary":"4月12日，吉利德科学(GILD)盘中上涨1.25%，截至02:08，报68.97美元/股，成交2.17亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将于(美东)盘后披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/12020840206400.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425341542","title":"吉利德科学下跌1.23%，报70.02美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425341542","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425341542?lang=zh_cn&edition=full","pubTime":"2024-04-05 02:35","pubTimestamp":1712255745,"startTime":"0","endTime":"0","summary":"4月5日，吉利德科学(GILD)盘中下跌1.23%，截至02:35，报70.02美元/股，成交2.25亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/05023540127771.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424846875","title":"吉利德科学下跌1.22%，报71.21美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424846875","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424846875?lang=zh_cn&edition=full","pubTime":"2024-04-04 02:30","pubTimestamp":1712169021,"startTime":"0","endTime":"0","summary":"4月4日，吉利德科学(GILD)盘中下跌1.22%，截至02:30，报71.21美元/股，成交1.73亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/04023040122363.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":-0.0151},{"period":"1month","weight":-0.0998},{"period":"3month","weight":-0.1613},{"period":"6month","weight":-0.1777},{"period":"1year","weight":-0.1979},{"period":"ytd","weight":-0.186}],"compareEarnings":[{"period":"1week","weight":0.0207},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0391},{"period":"6month","weight":0.2068},{"period":"1year","weight":0.2263},{"period":"ytd","weight":0.0731}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.041198},{"month":2,"riseRate":0.393939,"avgChangeRate":0.002047},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.009403},{"month":4,"riseRate":0.545455,"avgChangeRate":0.014133},{"month":5,"riseRate":0.5625,"avgChangeRate":0.021083},{"month":6,"riseRate":0.625,"avgChangeRate":0.024943},{"month":7,"riseRate":0.53125,"avgChangeRate":0.013302},{"month":8,"riseRate":0.53125,"avgChangeRate":0.033833},{"month":9,"riseRate":0.5625,"avgChangeRate":0.031735},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00096},{"month":11,"riseRate":0.625,"avgChangeRate":0.039318},{"month":12,"riseRate":0.40625,"avgChangeRate":0.011587}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}